LAUSR

REFERENCES 1. Wiesner T, Kutzner H, Cerroni L, Mihm MC Jr, Busam KJ, Murali R. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy. Pathology. 2016;48(2): 113-131. 2. Lian CG, Xu Y, Ceol C, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 2012;150(6):1135-1146. 3. Micevic G, Theodosakis N, Taube JM, Bosenberg MW, Rodi c N. Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas.Melanoma Res. 2017;27(2):85-96. 4. Rodic N, Zampella J, Sharma R, et al. Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytc proliferations. J Cutan Pathol. 2015;42(11):807-814. 5. Lee JJ, Vilain RE, Granter SR, et al. 5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms. J Cutan Pathol. 2017;44(3):249-255. 6. Siref AB, Huynh CAT, Balzer BL, Frishberg DP, Essner R, Shon W. Diagnostic utility of dual 5-hydroxymethylcytosine/Melan-A immunohistochemistry in differentiating nodal nevus from metastatic melanoma: an effective first-line test for the workup of sentinel lymph node specimen. J Cutan Pathol. 2019;46(4):261-266. 7. Uchiyama R, Uhara H, Uchiyama A, et al. 5-Hydroxymethylcytosine as a useful marker to differentiate between malignant melanomas and benign melanocytic nevi. J Dermatol Sci. 2014;73(2):161-163. 8. Larson AR, Dresser KA, Zhan Q, et al. Loss of 5hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors. Mod Pathol. 2014;27(7):936-944. 9. Lee J, Collins MK, Ko JY, et al. 5-Hydroxymethylcytosine immunoreactivity and molecular alterations in a spectrum of Spitzoid melanocytic neoplasms: a preliminary report. Oral abstract presented at: Annual Meeting of The American Society of Dermatopathology; October 26–29,2017; Baltimore, MD. 10. Yeh I. New and evolving concepts of melanocytic nevi and melanocytomas. Mod Pathol. 2020;33(Suppl 1):1-14.